Anupam Rasayan India Ltd

Anupam Rasayan India Limited reported strong Q1 FY27 results, with consolidated total income growing by 36% year-on-year to INR668 crores. Management highlighted key developments, including the commercialization of Ethyl Trifluoroacetate (ETFA) using flow chemistry, positioning the company as a global leader in fluorination chemistry. Strategic acquisitions, such as Jayhawk Fine Chemicals, have expanded the company's U.S. manufacturing capabilities and advanced chemistry expertise, while the proposed acquisition of Bliss GVS Pharma aims to build a comprehensive pharmaceutical platform. The company also signed a Letter of Intent with BASQUEVOLT for a potential USD300 million long-term supply contract. Financially, consolidated EBITDA rose 35% to INR175 crores, with EBITDA margins maintained at 26%. Management emphasized disciplined capital allocation, with major capex projects now completed. The company expects continued growth from high-value segments like performance materials and pharmaceuticals, supported by strong customer relationships and a robust product pipeline. The Bliss acquisition is expected to close by mid-September 2026, with integration to follow. The Agri business is expected to remain stable, while the semiconductor segment is showing strong traction. Management noted that the Agri segment's contribution will decrease as other segments grow faster, but it will maintain its own growth trajectory. The company also discussed plans for future acquisitions, including potential API facilities, though no specific targets were named. The earnings call concluded with management thanking participants and inviting further questions through the company's investor relations team.

The document emphasizes strong financial performance, strategic advancements, and positive outlook for future growth.